Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
MYQORZO is anticipated to be available in the US during the second half of January 2026.
Drug Development
J&J receives FDA approval for lung cancer therapy
EC approves Incyte’s Minjuvi combo for follicular lymphoma
Alnylam plans $250m investment in Norton manufacturing facility, US
Harbour BioMed and BMS sign multi-specific antibody collab
INCOG reveals $200m injectable drug expansion in Indiana
States consider payment limits to curb prescription drug prices with PDABs
LEO Pharma applies to EMA to expand Anzupgo use to adolescents
